Huang Xiaxuan, Zhang Luming, Xu Mengyuan, Yuan Shiqi, Ye Yan, Huang Tao, Yin Haiyan, Lyu Jun
Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Front Cardiovasc Med. 2022 Jul 19;9:948924. doi: 10.3389/fcvm.2022.948924. eCollection 2022.
Anti-Embolism (AE) devices therapy is an additional antithrombotic treatment that is effective in many venous diseases, but the correlations between this medical compression therapy and cardiovascular arterial disease or comorbid diabetes mellitus (DM) are still controversial. In this study we investigated the association between compression therapy and intensive care unit (ICU) mortality in patients with a first acute myocardial infarction (AMI) diagnosis complicated with type II DM.
This retrospective cohort study analyzed all patients with AMI and type II DM in the Medical Information Mart for Intensive Care-IV database. We extracted the demographics, vital signs, laboratory test results, comorbidities, and scoring system results of patients from the first 24 h after ICU admission. The outcomes of this study were 28-day mortality and ICU mortality. Analyses included Kaplan-Meier survival analysis, Cox proportional-hazards regression, and subgroup analysis.
The study included 985 eligible patients with AMI and type II DM, of who 293 and 692 were enrolled into the no-AE device therapy and AE device therapy groups, respectively. In the multivariate analysis, compared with no-AE device therapy, AE device therapy was a significant predictor of 28-day mortality (OR = 0.48, 95% CI = 0.24-0.96, = 0.039) and ICU mortality (OR = 0.50, 95% CI = 0.27-0.90, = 0.021). In addition to age, gender and coronary artery bypass grafting surgery, there were no significant interactions of AE device therapy and other related risk factors with ICU mortality and 28-day mortality in the subgroup analysis.
Simple-AE-device therapy was associated with reduced risks of ICU mortality and 28-day mortality, as well as an improvement in the benefit on in-hospital survival in patients with AMI complicated with type II DM.
抗栓装置（AE）疗法是一种额外的抗血栓治疗方法，对多种静脉疾病有效，但这种医学压迫疗法与心血管动脉疾病或合并糖尿病（DM）之间的相关性仍存在争议。在本研究中，我们调查了压缩疗法与首次急性心肌梗死（AMI）诊断并发II型糖尿病患者的重症监护病房（ICU）死亡率之间的关联。
这项回顾性队列研究分析了重症监护医学信息集市-IV数据库中所有患有AMI和II型糖尿病的患者。我们提取了患者入住ICU后最初24小时的人口统计学数据、生命体征、实验室检查结果、合并症和评分系统结果。本研究的结局指标为28天死亡率和ICU死亡率。分析包括Kaplan-Meier生存分析、Cox比例风险回归和亚组分析。
该研究纳入了985例符合条件的AMI和II型糖尿病患者，其中293例和692例分别纳入无AE装置治疗组和AE装置治疗组。在多变量分析中，与无AE装置治疗相比，AE装置治疗是28天死亡率（OR = 0.48，95%CI = 0.24-0.96，P = 0.039）和ICU死亡率（OR = 0.50，95%CI = 0.27-0.90，P = 0.021）的显著预测因素。在亚组分析中，除年龄、性别和冠状动脉搭桥手术外，AE装置治疗与其他相关危险因素与ICU死亡率和28天死亡率之间无显著交互作用。
简单的AE装置治疗与降低AMI并发II型糖尿病患者的ICU死亡率和28天死亡率风险相关，同时也改善了住院生存率。
